NEWS & INSIGHTS /

Emna Makhlouf, Chief of Staff: "Working with cancer survivors gives a lot of purpose to what we do"

Inside Cure51

The science

Publication Date:
TO READ NEXT

TechBio vs Biotech: What's the Difference? (Complete Guide)

In the last episode of Agathe Lecaron's podcast Ex-Vitro, our Chief of Staff Emna Makhlouf shares why our scientific approach feels positive.
A huge thank you to Agathe Lecaron for welcoming us on her podcast!

Emna Makhlouf, Chief of Staff


Updated: May 5, 2026

Table of Contents
in THIS ARTICLE
In this article

EMNA MAKHLOUF

Chief of Staff

MORE ARTICLES IN THIS TOPIC
RELATED ARTICLES

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

https://shining-circumstances-346837.framer.app/news/crispr-cas9-cancer-target-discovery

How CRISPR-Cas9 helps validate cancer targets

https://shining-circumstances-346837.framer.app/news/crispr-cas9-cancer-target-discovery

How CRISPR-Cas9 helps validate cancer targets

yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

yann-bizien-chloe-abadachi-cancer

Yann Bizien: 9 Years After a Stage IV Pancreatic Cancer Diagnosis

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

READ MORE

MORE TOP STORIES
marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

Building a Product Ecosystem for Cancer Target Discovery

CHUV-Centre-hospitalier-universitaire-vaudois

CHUV Lausanne received their Rosalind trophy!

precision-medicine-nicolas-wolikow

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

NEWS & INSIGHTS

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

We’re thrilled to announce a major milestone for Cure51: a strategic collaboration with Servier to uncover new therapeutic targets in glioblastoma

READ MORE

MORE TOP STORIES

Cure51 and Servier sign a long-term Target ID partnership on Glioblastoma in a deal up to €442M per target to discover novel therapies.

Building a Product Ecosystem for Cancer Target Discovery

marine-otero-del-val-chloe-monvoisin-nicolas-bonneau-cure51-product

CHUV Lausanne received their Rosalind trophy!

CHUV-Centre-hospitalier-universitaire-vaudois

Our CEO Nicolas Wolikow: "Turning precision medicine into an operational reality"

precision-medicine-nicolas-wolikow

How Cure51 Builds a Global Cancer Research Project Across 50+ Countries

Global-Cancer-Research-Compliance

NEWS & INSIGHTS

Follow us

Linkedin

Facebook

Instagram

Contact us

Contact us

Follow us

Linkedin

Facebook

Instagram

Contact us

ROSALIND

Contact us